Cancer immunotherapy has emerged as a revolutionary approach in the treatment of various malignancies, harnessing the power of the immune system to target and eliminate cancer cells. Among the innovative strategies within this field, Bispecific T-cell Engagers (BiTEs) represent a cutting-edge technology designed to recruit and activate T-cells, the body's primary immune effector cells, to specifically target and kill tumor cells. BiTEs exemplify the concept of redirecting the immune system's intrinsic capabilities toward malignant cells by leveraging the specificity of antibodies and the potent cytotoxic functions of T-cells.
Bispecific T-cell Engagers (BiTEs) are a type of immunotherapy designed to redirect T-cells to tumor cells, facilitating targeted cytotoxicity. This approach leverages the specificity of antibodies and the potent effector functions of T-cells to achieve anti-tumor effects.

Stay curious, stay innovative. I'm Luke McLaughlin.

If you would like to learn more about this topic consider reading our full length articles on www.biotechnologyreviews.com
Or consider our podcast series on youtube or Spotify at our Biotechnology Reviews Channel.
Our articles are also available on our linkedin newsletter Biotechnology Reviews.


https://www.linkedin.com/pulse/bispecific-t-cell-engagers-bites-detailed-technical-luke-mclaughlin-rbu6f/?trackingId=xZeAux53SCihwXcF6fCS1g%3D%3D

Ver todos los episodios